Is it known how cosentyx influences vaccine protection?

Does Cosentyx Reduce Vaccine Effectiveness?

Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis and other conditions, impairs immune responses to certain vaccines. Clinical studies show it reduces antibody production against non-live vaccines like tetanus toxoid and influenza, with titers often 20-50% lower than in healthy controls.[1][2] Live vaccines are contraindicated due to infection risk.[3]

How Does It Affect Specific Vaccines?

- Influenza vaccine: Seroprotection rates drop, especially in psoriasis patients; one trial found 40-60% response vs. 80%+ in placebo.[1]
- Pneumococcal vaccine: Lower antibody levels post-vaccination in treated patients.[2]
- COVID-19 vaccines: Real-world data indicate reduced neutralizing antibodies, though clinical protection against severe disease holds in most cases.[4]
Timing matters—vaccinate before starting Cosentyx or during treatment windows when possible.

What Do Guidelines Recommend?

Novartis advises avoiding live vaccines and monitoring responses to non-live ones. Rheumatology societies like ACR suggest pre-treatment vaccination and annual influenza shots despite reduced efficacy.[3][5] No routine post-vaccination antibody testing is mandated, but it's considered for high-risk patients.

Any Long-Term or Reversal Effects?

Efficacy wanes with ongoing Cosentyx use, but pausing therapy (washout period ~12 weeks) can restore responses partially.[2] No data shows permanent impairment after discontinuation.

Sources
[1] van de Vooren et al., Vaccine 2017
[2] Baden et al., Ann Rheum Dis 2018
[3] Cosentyx Prescribing Information, Novartis
[4] Deepak et al., medRxiv 2021 (COVID data)
[5] ACR Vaccination Guidance 2023